- Home
- ZION vs TWST Comparison
ZION vs TWST Comparison
Compare ZION & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | TWST |
|---|---|---|
| Founded | 1873 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 9.2B |
| IPO Year | 2012 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ZION | TWST |
|---|---|---|
| Price | $63.25 | $133.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 13 |
| Target Price | $72.73 | ★ $163.67 |
| AVG Volume (30 Days) | 1.4M | ★ 2.8M |
| Earning Date | 10-19-2026 | 11-13-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | 21.41 | ★ 63.89 |
| EPS | ★ 4.61 | N/A |
| Revenue | ★ $662,000,000.00 | $376,572,000.00 |
| Revenue This Year | $5.90 | $21.17 |
| Revenue Next Year | $2.31 | $20.24 |
| P/E Ratio | $13.67 | ★ N/A |
| Revenue Growth | 3.60 | ★ 20.32 |
| 52 Week Low | $48.50 | $23.30 |
| 52 Week High | $73.34 | $219.71 |
Technical Indicators
Market Signals| Indicator | ZION | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 38.61 |
| Support Level | $60.80 | $117.74 |
| Resistance Level | $63.94 | $155.44 |
| Average True Range (ATR) | 1.16 | 15.61 |
| MACD | 0.22 | -6.30 |
| Stochastic Oscillator | 64.60 | 2.65 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.